Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback